TY - JOUR
T1 - Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma
AU - Santoro, Armando
AU - Mazza, Rita
AU - Pulsoni, Alessandro
AU - Re, Alessandro
AU - Bonfichi, Maurizio
AU - Zilioli, Vittorio Ruggero
AU - Zanni, Manuela
AU - Merli, Francesco
AU - Anastasia, Antonella
AU - Luminari, Stefano
AU - Annechini, Giorgia
AU - Gotti, Manuel
AU - Peli, Annalisa
AU - Liberati, Anna Marina
AU - Di Renzo, Nicola
AU - Castagna, Luca
AU - Giordano, Laura
AU - Ricci, Francesca
AU - Carlo-Stella, Carmelo
PY - 2020/1/14
Y1 - 2020/1/14
N2 - The complete remission (CR) rate achieved with induction chemotherapy prior to autologous stem cell transplantation (ASCT) represents the strongest prognostic factor in relapsed/ refractory (R/R) classical Hodgkin lymphoma (cHL). By inducing a CR rate of 75%, the bendamustine, gemcitabine, vinorelbine (BEGEV) regimen represents an optimal chemotherapy regimen prior to ASCT. Presented here are the 5-year results of BEGEV followed by ASCT in R/R cHL. With a median follow-up of 5 years, progression-free survival (PFS) and overall survival (OS) for the whole series (n 5 59) were 59% and 78%, respectively. ASCT was performed in 43 of 49 responding patients (73% by intention to treat [ITT]; 88% by response to BEGEV) and resulted in 33 with continuous CR (56% by ITT; 77% of transplanted patients), 7 with disease relapse, and 3 with nonrelapse mortality. For patients who received transplants, the 5-year PFS and OS were 77% and 91%, respectively, with no significant difference between relapsed and refractory patients. No patient experienced secondary leukemia or myelodysplasia. In summary, the long-term efficacy data, the benefits for both relapsed and refractory patients, and the excellent safety profile provide a strong rationale for further development of the BEGEV regimen.
AB - The complete remission (CR) rate achieved with induction chemotherapy prior to autologous stem cell transplantation (ASCT) represents the strongest prognostic factor in relapsed/ refractory (R/R) classical Hodgkin lymphoma (cHL). By inducing a CR rate of 75%, the bendamustine, gemcitabine, vinorelbine (BEGEV) regimen represents an optimal chemotherapy regimen prior to ASCT. Presented here are the 5-year results of BEGEV followed by ASCT in R/R cHL. With a median follow-up of 5 years, progression-free survival (PFS) and overall survival (OS) for the whole series (n 5 59) were 59% and 78%, respectively. ASCT was performed in 43 of 49 responding patients (73% by intention to treat [ITT]; 88% by response to BEGEV) and resulted in 33 with continuous CR (56% by ITT; 77% of transplanted patients), 7 with disease relapse, and 3 with nonrelapse mortality. For patients who received transplants, the 5-year PFS and OS were 77% and 91%, respectively, with no significant difference between relapsed and refractory patients. No patient experienced secondary leukemia or myelodysplasia. In summary, the long-term efficacy data, the benefits for both relapsed and refractory patients, and the excellent safety profile provide a strong rationale for further development of the BEGEV regimen.
UR - http://www.scopus.com/inward/record.url?scp=85078140748&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078140748&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2019000984
DO - 10.1182/bloodadvances.2019000984
M3 - Article
C2 - 31935284
AN - SCOPUS:85078140748
SN - 2473-9529
VL - 4
SP - 136
EP - 140
JO - Blood advances
JF - Blood advances
IS - 1
ER -